Wijesuriya Nadeev, Elliott Mark K, Mehta Vishal, Behar Jonathan M, Niederer Steven, Wilkoff Bruce L, Rinaldi Christopher A
School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom.
Department of Cardiology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Front Physiol. 2022 Aug 11;13:993604. doi: 10.3389/fphys.2022.993604. eCollection 2022.
Conduction System Pacing (CSP) delivered by His Bundle Pacing (HBP) or Left Bundle Pacing (LBP) are exciting novel interventions in the field of Cardiac Resynchronization Therapy (CRT). As the evidence base for CSP grows, the volume of implants worldwide is projected to rise significantly in the coming years. As such, physicians will be confronted with increasingly prevalent and vital issues arising in long-term follow up, including the management of infected, malfunctioning, or redundant CSP leads. Transvenous lead extraction (TLE) is the first-line option for removal of pacing leads when indicated in these circumstances. The evidence base for TLE in the context of CSP is still in its infancy. In this article, we first provide a brief overview of TLE. We then examine the data on the long-term performance of HBP leads. Next, we describe the features of the Medtronic Select Secure 3,830 lead, and how experience of TLE of this lead in the paediatric population has informed our practice. Finally, we review the current evidence for TLE in HBP and LBP, and discuss how future studies can address gaps in our current knowledge.
通过希氏束起搏(HBP)或左束支起搏(LBP)进行的传导系统起搏(CSP)是心脏再同步治疗(CRT)领域令人兴奋的新型干预措施。随着CSP证据基础的不断扩大,预计未来几年全球植入量将显著增加。因此,医生将面临长期随访中日益普遍且至关重要的问题,包括感染、故障或多余的CSP导线的管理。经静脉导线拔除(TLE)是在这些情况下有指征时拔除起搏导线的一线选择。CSP背景下TLE的证据基础仍处于起步阶段。在本文中,我们首先简要概述TLE。然后我们研究HBP导线长期性能的数据。接下来,我们描述美敦力Select Secure 3830导线的特点,以及该导线在儿科人群中的TLE经验如何为我们的实践提供参考。最后,我们回顾HBP和LBP中TLE的当前证据,并讨论未来研究如何填补我们现有知识的空白。